Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review
May 06, 2015 at 09:20 AM EDT
In a report published Wednesday, Baird analysts upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT). The price target was raised from $16 ...
